Entity

Time filter

Source Type

Lárisa, Greece

Vageli D.P.,University of Thessaly | Doukas S.G.,University of Thessaly | Markou A.,General Hospital of Larissa
Pediatric Blood and Cancer | Year: 2013

Mismatch DNA repair (MMR) mRNA expression analysis was performed on a biopsy of oral mucosa melanin pigmentation lesion, a hamartomatous polyp and peripheral blood derived from a 12-year-old child with Peutz-Jeghers Syndrome (PJS). We present a deficient MMR system, in a PJS patient, which demonstrated low mRNA levels of hMSH6 and hPMS2 and an increasing MMR deficiency from the non-dysplastic lesion to hamartomatous polyp of PJS with a high risk of cancer. Pediatr Blood Cancer 2013;60:E116-E117. © 2013 Wiley Periodicals, Inc. Source


Hantes M.E.,University Hospital of Larissa | Venouziou A.,University Hospital of Larissa | Bargiotas K.A.,University Hospital of Larissa | Metafratzi Z.,General Hospital of Larissa | And 2 more authors.
Arthroscopy - Journal of Arthroscopic and Related Surgery | Year: 2010

Purpose: The purpose of this study was to determine quantitatively whether the Latarjet procedure (coracoid transfer to the glenoid) is sufficient to restore a significant defect area of the glenoid. Methods: Fourteen cadaveric shoulders were used (mean age, 76 years; range, 72 to 87 years). An anteroinferior glenoid defect was created and then the coracoid osteotomized to its angle and transferred to the defect. A 3-dimensional computed tomography scan was used to calculate the surface area of (1) the intact glenoid, (2) the osteotomized glenoid, and (3) the reconstructed glenoid. Results: The mean area of the intact inferior glenoid was 734 ± 89 mm 2. After creation of the defect, the surface area of the glenoid was reduced significantly to 523 ± 55 mm 2 (P = .011). The mean defect area was 28.7% ± 6% of the intact glenoid. After coracoid transfer, the mean surface area of the reconstructed glenoid was 708 ± 71 mm 2 but it was not significantly smaller than that of the intact glenoid (P = .274). The mean surface area of the coracoid that was used to repair the defect was 198 ± 34 mm 2, or 27% ± 5% of the intact glenoid. Conclusions: In our cadaveric model, a mean 29% defect size of the inferior glenoid was restored to normal after coracoid transfer by use of the Latarjet procedure. Clinical Relevance: In the clinical scenario, the existence of a glenoid bone defect of more than 25% to 30% is very rare in patients with anterior shoulder instability. Therefore, when clinically indicated, large bony defects of the anterior glenoid can be adequately treated by the Latarjet procedure. © 2010 Arthroscopy Association of North America. Source


Koutsiaris A.G.,Technological Educational Institute of Larissa | Tachmitzi S.V.,General Hospital of Larissa | Batis N.,Technological Educational Institute of Larissa
Microvascular Research | Year: 2013

Blood volume flow (Q), wall shear rate (WSR) and wall shear stress (WSS) were quantified, for the first time, in the conjunctival pre-capillary arterioles of normal human volunteers with diameters (D) between 6 and 12μm. The variation of the blood velocity throughout the cardiac cycle was taken into account using high speed video microcinematography. The dual effect of arteriolar diameter, firstly on the WSR and secondly on the dynamic viscosity of blood, was taken into account in the estimation of WSS. The average Q, WSR and WSS, throughout the cardiac cycle ranged from 13 to 202 pl/s, 587 to 3515s-1 and 1.7 to 21.1N/m2 respectively. The best fit power law equations, giving the increase of Q and the decrease of WSR and WSS with diameter, are presented for the systolic and diastolic phase as well as for the averages throughout the cardiac cycle. According to the WSS best fit equation, the average WSS decreases from 10.5N/m2 at D=6μm down to 2.1N/m2 at D=12μm. © 2012 Elsevier Inc. Source


Kokouva M.,University of Thessaly | Bitsolas N.,University of Thessaly | Hadjigeorgiou G.M.,University of Thessaly | Rachiotis G.,University of Thessaly | And 2 more authors.
BMC Public Health | Year: 2011

Background. The causality of lymphohaematopoietic cancers (LHC) is multifactorial and studies investigating the association between chemical exposure and LHC have produced variable results. The aim of this study was to investigate the relationships between exposure to pesticides and LHC in an agricultural region of Greece. Methods. A structured questionnaire was employed in a hospital-based case control study to gather information on demographics, occupation, exposure to pesticides, agricultural practices, family and medical history and smoking. To control for confounders, backward conditional and multinomial logistic regression analyses were used. To assess the dose-response relationship between exposure and disease, the chi-square test for trend was used. Results. Three hundred and fifty-four (354) histologically confirmed LHC cases diagnosed from 2004 to 2006 and 455 sex- and age-matched controls were included in the study. Pesticide exposure was associated with total LHC cases (OR 1.46, 95% CI 1.05-2.04), myelodysplastic syndrome (MDS) (OR 1.87, 95% CI 1.00-3.51) and leukaemia (OR 2.14, 95% CI 1.09-4.20). A dose-response pattern was observed for total LHC cases (P = 0.004), MDS (P = 0.024) and leukaemia (P = 0.002). Pesticide exposure was independently associated with total LHC cases (OR 1.41, 95% CI 1.00 - 2.00) and leukaemia (OR 2.05, 95% CI 1.02-4.12) after controlling for age, smoking and family history (cancers, LHC and immunological disorders). Smoking during application of pesticides was strongly associated with total LHC cases (OR 3.29, 95% CI 1.81-5.98), MDS (OR 3.67, 95% CI 1.18-12.11), leukaemia (OR 10.15, 95% CI 2.15-65.69) and lymphoma (OR 2.72, 95% CI 1.02-8.00). This association was even stronger for total LHC cases (OR 18.18, 95% CI 2.38-381.17) when eating simultaneously with pesticide application. Conclusions. Lymphohaematopoietic cancers were associated with pesticide exposure after controlling for confounders. Smoking and eating during pesticide application were identified as modifying factors increasing the risk for LHC. The poor pesticide work practices identified during this study underline the need for educational campaigns for farmers. © 2011 Kokouva et al; licensee BioMed Central Ltd. Source


Makris D.,University Hospital of Larissa | Manoulakas E.,University Hospital of Larissa | Komnos A.,General Hospital of Larissa | Papakrivou E.,University Hospital of Larissa | And 5 more authors.
Critical Care Medicine | Year: 2011

Objective: To investigate whether the use of pravastatin reduces the frequency of ventilator-associated pneumonia and whether it is related to favorable outcomes in critical care patients. Design: Two-center, two-arm, randomized, open-label, controlled trial. Setting: University Hospital and General Hospital of Larissa, Greece. Patients: Consecutive patients were recruited from the intensive care units of the two hospitals. Patient inclusion criteria included mechanical ventilation and intensive care unit stay of >48 hrs. Interventions: The two arms consisted of treatment plus oral pravastatin sodium (40 mg) (n = 71 patients, pravastatin group) and treatment without pravastatin (n = 81 patients, control group). Treatment was started after randomization and ended 30 days later. Measurements and Main Results: Ventilator-associated pneumonia frequency and intensive care unit mortality at 30 days and at the end of intensive care unit stay were measured. Adverse events related to statin treatment in the intensive care unit were documented. Sixteen patients (22.5%) in the pravastatin group and 28 (34.5%) in the control group (p = .11) presented pneumonia during the 30-day treatment period in the intensive care unit. There was an indication for increased probability of being free from ventilator-associated pneumonia during the 30-day treatment period in the pravastatin group compared to the control group (p = .06) and significantly increased probability during the whole intensive care unit period of stay (p = .04) in the pravastatin group compared to the control group in the subgroup of patients with Acute Physiology and Chronic Health Evaluation scores of ≥15. Six patients (8.45%) in the pravastatin group and 16 (19.85%) in the control group died during the 30-day treatment period (p = .06), whereas 10 (14.1%) patients in the pravastatin group and 24 (29.1%) patients in the control group died during the whole period of intensive care unit stay (p = .03). Pravastatin group patients with Acute Physiology and Chronic Health Evaluation scores of ≥15 had significantly increased probability of survival compared to controls during the 30-day treatment period (p = .04). Creatine kinase and hepatic function enzyme levels during the whole study period were not significantly different between the pravastatin group and control group. Conclusion: This study provides evidence that pravastatin may favorably affect the outcome of critical care patients. © 2011 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins. Source

Discover hidden collaborations